Pharma brand acquisition case study: Amgen to acquire Celgene’s Otezla
Amgen announced today that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers... Read More
USFDA Approves Amgen’s Trastuzumab Biosimilar, Kanjinti
The FDA has approved Amgen’s ABP 980, a trastuzumab biosimilar referencing Herceptin. The drug, trastuzumab-anns, will be sold as Kanjinti. Kanjinti was approved for... Read More
AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Posted on17 Dec 2018
TagsAbbVie, Amgen, biosimilar of sandoz, Boehringer Ingelheim, Fresenius Kabi, humira, Merck, Momenta, Mylan, novartis, Novartis’ Sandoz, Samsung Bioepis, sandoz
Comments0
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting... Read More
Amgen & UCB ‘s Romosozumab: Development Pathway and approval status
Amgen and UCB, a global biopharmaceutical company, announced the resubmission of the Biologics License Application (BLA) to the US Food and Drug... Read More
Amgen’s Amgevita, biosimilar of AbbVie’s Humira (adalimumab), has been approved by the European Commission
Reference Biologic – Humira (adalimumab) of AbbVie Biosimilar – Amgevita (adalimumab) of Amgen European Commission (EC) has granted marketing authorization for AMGEVITA™... Read More
2017 USFDA New Drug Approval: Amgen’s Parsabiv™ (Etelcalcetide)
U.S. Food and Drug Administration (FDA) has approved Amgen’s Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with... Read More
Amgen and Advaxis enter global cancer immunotherapies collaboration
Amgen and Advaxis, announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment... Read More
Amgen got USFDA Approval For Once-Monthly Cholesterol-lowering Evolocumab (Repatha) Device
The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a... Read More
Strategic Deal : Amgen Regain Rights of Prolia, Xgeva & Vectibix brands from Glaxo
About the deal: Amgen has entered into a definitive agreement with GlaxoSmithKline plc. Under this agreement, Amgen will regain all remaining rights... Read More
Amgen to Acquire Dezima Pharma for $1.55B
Amgen and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement under which Amgen will... Read More